Chimerix Reports Fourth Quarter and Year End 2023 Financial

– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 –

Related Keywords

United States , American , Lisa Decker , Pablo Lee , Mike Andriole , American Society Of Clinical Oncology , National Institutes Of Health , Oncology Consortium , Exchange Commission , Reiterate Interim , Peer Reviewed Journal , Clinical Oncology , Conference Call , Chief Executive Officer , Michelle Laspaluto , Chief Financial Officer , Tom Riga , Chief Operating , Commercial Officer , Vice President , Diffuse Midline Glioma , American Society , Response Assessment , National Institutes , Pacific Pediatric Neuro Oncology Consortium , Emergent Biosolutions , Private Securities Litigation Reform Act , Months Ended December , Ended December , Region ,